Investors on the hunt for high-growth opportunities have their work cut out for them as cannabis stocks have started to look more like normal equities at the midway point in 2019. The slim TSX tech sector, aside from Shopify’s incredible run, has been unpredictable. We are going to veer away from these sectors today and look at two stocks that should attract the interest of investors on the hunt for big potential growth.
Zymeworks (TSX:ZYME)(NYSE:ZYME) rose above the $30 mark for the first time in 2019 in early July. The Vancouver-based biotechnology company boasts two product candidates that have attracted a great deal of interest over the past year. Those are ZW25, which just entered Phase II Trials, and ZW49, which just received approval for Phase I Trials.
When the year started, I’d recommended that investors look to scoop up Zymeworks for the long haul. As well as the stock has performed in 2019, it is possible that Zymeworks has not even scratched the surface of its potential.
Zymeworks closed a public offering in late June that it will use to expand the global development of ZW25. The drug has game-changing potential in the breast cancer therapeutics market. Beyond that, Zymeworks boasts a deep pipeline of partnerships and assets that will fuel revenue for the foreseeable future.
Zymeworks topped out its 52-week at the time of this writing, but I’m bullish on the stock as we look ahead to the next decade. Shares may be pricey in the near term, as its RSI suggests it is on the edge of technically overbought territory, but investors seeking growth should look for an entry point in the second half of 2019.
5 TSX Stocks Under $5Click here to learn more!
Stars Group (TSX:TSGI)(NASDAQ:TSG) stock has halved its value from the all-time highs it reached in the summer of 2018. The company had a strong 2018, but splurged on acquisitions, which in turn weighed on earnings. Stars Group has moved aggressively into European and Australian markets. Of course, the big story over the past year has been its effort to establish a foothold in legalized sports gambling in the United States.
The recent partnership with FOX Sports holds huge promise as both hope to win big in the growing US sports betting market. More states are expected to follow through with legalization before the end of this year. A Zion Market Research report recently projected that the global sports betting market would reach $155.5 billion by 2024, which represents a solid CAGR of 8.8% from 2018 to 2024.
Stars Group is well positioned to benefit from growth in the US market and internationally. It will take time for the U.S. market to mature, but investors who exercise patience could be well rewarded. Stars Group is currently trading at the low end of its 52-week range. Investors can expect its second quarter 2019 results to be released in August. Stars Group stock is worth the gamble at the midway point in 2019.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. Tom Gardner owns shares of Shopify. The Motley Fool owns shares of Shopify and Shopify. Shopify is a recommendation of Stock Advisor Canada.